Common Stock, par value $0.0001 per share
- Symbol
- RNAZ
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
TransCode Therapeutics, Inc.
RNAZNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 5, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing, in collaboration with Quantum Leap Healthcare Collaborative, the submission to the U.S. Food and Drug Administration of an Investigational New Drug application amendment for a planned Phase 2a clinical trial with TransCode’s lead therapeutic candidate, TTX-MC138.…
Company context
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.
Current securities
Recent company filings
- Other EventsOct 28, 2026
- Entry into a Material Definitive Agreement · Triggering Events That Accelerate or Increase a Direct Financial ObligationOct 1, 2026
- Other EventsSep 28, 2026
- 3 filingSep 21, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
Registered securities in this filing
TRANSCODE THERAPEUTICS, INC. · 8-K · Filed 2026-02-05
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On February 5, 2026, TransCode Therapeutics, Inc.
(“TransCode”) issued a press release announcing, in collaboration with Quantum Leap Healthcare Collaborative, the submission
to the U.S. Food and Drug Administration of an Investigational New Drug application amendment for a planned Phase 2a clinical trial with
TransCode’s lead therapeutic candidate, TTX-MC138. A copy of this press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K.
The information in this Item 7.01, including
Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”),
or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 BOSTON, February 05, 2026 - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode’s lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program’s first expansion into colorectal cancer. As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and have positive markers for circulating tumor DNA (ctDNA). Recent studies have demonstrated that ctDNA is a prognostic marker of cancer recu…
Open exhibit ↗